KR20210139293A - 폐동맥 고혈압 및 연관 폐동맥 고혈압 치료방법 및 매일 투여 - Google Patents

폐동맥 고혈압 및 연관 폐동맥 고혈압 치료방법 및 매일 투여 Download PDF

Info

Publication number
KR20210139293A
KR20210139293A KR1020217031156A KR20217031156A KR20210139293A KR 20210139293 A KR20210139293 A KR 20210139293A KR 1020217031156 A KR1020217031156 A KR 1020217031156A KR 20217031156 A KR20217031156 A KR 20217031156A KR 20210139293 A KR20210139293 A KR 20210139293A
Authority
KR
South Korea
Prior art keywords
diazaspiro
pyrimidin
decane
biphenyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020217031156A
Other languages
English (en)
Korean (ko)
Inventor
마그달레나 알론소-갈리시아
데이비드 카펜터
토마스 팩
멜리사 로즈
줄리 루르카
스티브 윙
Original Assignee
알타반트 사이언시스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알타반트 사이언시스 게엠베하 filed Critical 알타반트 사이언시스 게엠베하
Publication of KR20210139293A publication Critical patent/KR20210139293A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217031156A 2019-03-15 2020-03-13 폐동맥 고혈압 및 연관 폐동맥 고혈압 치료방법 및 매일 투여 Abandoned KR20210139293A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819162P 2019-03-15 2019-03-15
US62/819,162 2019-03-15
PCT/IB2020/000177 WO2020188352A1 (en) 2019-03-15 2020-03-13 A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing

Publications (1)

Publication Number Publication Date
KR20210139293A true KR20210139293A (ko) 2021-11-22

Family

ID=71092560

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217031156A Abandoned KR20210139293A (ko) 2019-03-15 2020-03-13 폐동맥 고혈압 및 연관 폐동맥 고혈압 치료방법 및 매일 투여

Country Status (9)

Country Link
US (2) US11576915B2 (https=)
EP (1) EP3938043A1 (https=)
JP (1) JP2022525202A (https=)
KR (1) KR20210139293A (https=)
CN (1) CN113784717A (https=)
AU (1) AU2020244278A1 (https=)
CA (1) CA3133589A1 (https=)
MX (1) MX2021011224A (https=)
WO (1) WO2020188352A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022507533A (ja) * 2018-11-16 2022-01-18 アルタバント・サイエンシズ・ゲーエムベーハー 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
US11607413B2 (en) * 2019-01-30 2023-03-21 Altavant Sciences Gmbh Dosage regime and method for treating pulmonary arterial hypertension
US11576915B2 (en) 2019-03-15 2023-02-14 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
WO2023062595A1 (en) * 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101815534A (zh) * 2007-07-11 2010-08-25 莱西肯医药有限公司 用于治疗肺动脉高压以及相关疾病和病症的方法和组合物
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
US9399741B2 (en) 2013-10-09 2016-07-26 Uop Llc Methods and apparatuses for desulfurizing hydrocarbon streams
KR20210102887A (ko) * 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
JP2022507533A (ja) * 2018-11-16 2022-01-18 アルタバント・サイエンシズ・ゲーエムベーハー 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
US20200188399A1 (en) 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating interstitial lung disease
WO2020128608A1 (en) * 2018-12-17 2020-06-25 Altavant Sciences Gmbh Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension
US11607413B2 (en) 2019-01-30 2023-03-21 Altavant Sciences Gmbh Dosage regime and method for treating pulmonary arterial hypertension
US11576915B2 (en) 2019-03-15 2023-02-14 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing

Also Published As

Publication number Publication date
US11576915B2 (en) 2023-02-14
US20200289510A1 (en) 2020-09-17
AU2020244278A1 (en) 2021-09-30
JP2022525202A (ja) 2022-05-11
EP3938043A1 (en) 2022-01-19
US20240024316A1 (en) 2024-01-25
WO2020188352A1 (en) 2020-09-24
CN113784717A (zh) 2021-12-10
CA3133589A1 (en) 2020-09-24
MX2021011224A (es) 2021-12-10

Similar Documents

Publication Publication Date Title
US11911382B2 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
US20240024316A1 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
US8642661B2 (en) Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists
US9522129B2 (en) Pharmaceutical Combination
US20220096475A1 (en) Method for treating sarcoidosis-associated pulmonary hypertension
CN104667283A (zh) 一种治疗血脂异常和动脉粥样硬化的复方药物组合
WO2021074284A1 (fr) Utilisation de nictotinamide mononucléotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes
JP2015512919A (ja) 塩酸レルカニジピンおよびロサルタンカリウム配合剤およびその調製法
CN110290788A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
AU2016301689B2 (en) Ameliorating agent for detrusor hyperactivity with impaired contractility
HK40065546A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
JP7257091B2 (ja) 認知症の治療及び予防薬
HK40058221A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
MXPA06008180A (es) Metodo para tratar disfuncion erectil.
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
JP2019182845A (ja) キヌレニンアミノトランスフェラーゼ２（ｋａｔ２）阻害剤
WO2005117853A1 (ja) 高脂血症治療剤及び糖尿病治療剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1902 Submission of document of abandonment before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1902